The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare efficacy and safety of candesartan and losartan in hypertension with heart failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure

NCT01682564

Hypertension Congestive Heart Failure

COMPLETED PHASE4

A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

NCT04521023

Hypertension

COMPLETED PHASE4

Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

NCT02651870

Hypertension

COMPLETED PHASE3

Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

NCT02988362

Hypertension

COMPLETED PHASE1

The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.

NCT01828359

Hypertension

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, open-label, phase 4 study. wash out periods need at least 14 days if the patients take ARB or ACE inhibitor to control Blood pressure. Patients take Candemore or Cozzar once a day during 16 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Candemore tablet

Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks

Group Type EXPERIMENTAL

Candemore tablet

Intervention Type DRUG

Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.

dosage is depends on the sitting blood pressure.

Cozzar tablet

Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks

Group Type ACTIVE_COMPARATOR

Cozzar tablet

Intervention Type DRUG

Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Candemore tablet

Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.

dosage is depends on the sitting blood pressure.

Intervention Type DRUG

Cozzar tablet

Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female and male patients who aged above 19 and below 75
* Patients with 90\~109mmHg average sitting DBP on baseline
* NYHA class 2\~4
* Patients who agreement with written informed consent

Exclusion Criteria

* above 110mmHg sitting DBP and/or 180mmHg sitting SBP
* Patients who have difference values that above 20mmHg sitting SBP or 10mmHg sitting DBP in both arms on screening
* Patients who have medical history that secondary hypertension or rule out secondary hypertension
* malignant hypertension
* symptomatic postural hypotension
* right heart failure due to pulmonary disease
* etc.

Minimum Eligible Age

19 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No